Dauntless Pharmaceuticals & Aegis Therapeutics Announce Licensing Agreement
Dauntless Pharmaceuticals, Inc. and Aegis Therapeutics, LLC recently announced a licensing agreement providing Dauntless’ access to Aegis’ Intravail drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Financial terms were not disclosed.
“We are fortunate to be able to access Aegis’ proprietary Intravail drug delivery technologies for an application that will benefit cancer patients,” said Joel F. Martin, President and CEO of Dauntless. “We have the option of licensing the Intravail technology for additional drugs and are looking at a number of exciting opportunities.”
Edward T. Maggio, Chief Executive Officer of Aegis, “The team at Dauntless has a track record of rapid, cost-effective clinical development, and we are delighted to work with them on this new venture. Dauntless has several innovative ideas to develop additional drugs formulated with Intravail, and we are excited by the prospects of expanding the portfolio.”
Dauntless Pharmaceuticals is a company founded by Sofinnova Ventures that manages the development of multiple clinical assets, using a separate corporation for each. This enables the optimal structuring of financial, human, and development resources as well as acquisitions and partnerships. Dauntless’ approach reduces fixed costs while leveraging project-specific human capital and external service providers. Dauntless has access to broad industry expertise and sources of capital that can speed the development of new specialty products to the benefit of entrepreneurs and inventors. For more information, visit www.dauntlessph.com.
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Its patented Intravail drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular and small molecule therapeutics via the intranasal administration route with exceptionally high and unmatched bioavailability that can currently only be achieved by injection. For more information, visit www.aegisthera.com.
Total Page Views: 1214
